drugset / Trial / NCT00665834

Comparison of Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome

NCT00665834

Phase 4 Completed 18 enrolled Queen's University AstraZeneca · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a 3-month, randomized, parallel-group study with 2 periods, comparing the efficacy and the safety of rosuvastatin 20 mg versus atorvastatin 80 mg in patients with an acute coronary syndrome (ACS).

Timeline

Start
2006-04
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 80 mg
Comparator Rosuvastatin Small molecule 20 mg